4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

28 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

04 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

29 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

12 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

06 Feb 2024 23:27:14 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

05 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

03 Feb 2024 17:00:00 By Nasdaq GlobeNewswire

4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden

29 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease

23 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

04 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

03 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD

21 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference

04 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

15 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights

09 Nov 2023 16:19:53 By Nasdaq GlobeNewswire

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC

01 Nov 2023 16:00:00 By Nasdaq GlobeNewswire

4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy

30 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC

25 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD

23 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

4DMT Appoints Uneek Mehra as Chief Financial and Business Officer

12 Sep 2023 16:05:00 By Nasdaq GlobeNewswire